Involvement of AMP-activated Protein Kinase and Death Receptor 5 in TRAIL-Berberine-induced Apoptosis of Cancer Cells

Overview

Journal Sci Rep

Specialty Science

Date 2018 Apr 5

PMID 29615720

Citations 13

Authors

Rong Ke

Kanchan Vishnoi

Navin Viswakarma

Sreevidya Santha

Subhasis Das

Ajay Rana

Basabi Rana

Affiliations

Soon will be listed here.

Abstract

Our previous studies indicated that combination of Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and PPARγ ligand Troglitazone (TZD), can induce significant apoptosis in various TRAIL-resistant prostate and hepatocellular carcinoma (HCC) cells. These also suggested serine/threonine kinase AMP-activated protein kinase (AMPK) to be a mediator of TRAIL-TZD-induced apoptosis. To further validate AMPK's role in TRAIL sensitization, we determined the apoptotic potential of TRAIL in combination with the natural compound Berberine (BBR), the latter being a potent activator of AMPK. These demonstrated a significant reduction of cell viability and induction of apoptosis (increased cleavage of caspase 3, 8, 9) when treated with TRAIL-BBR combination. This apoptosis is attenuated in cells overexpressing AMPKα-dominant negative (DN) or following AMPKα knockdown, confirming involvement of AMPK. To identify potential downstream mediators involved, an apoptosis RT PCR array analysis was performed. These showed induction of several genes including TNFRSF10B (expresses DR5) and Harakiri following BBR treatment, which were further validated by qPCR analysis. Furthermore, knocking down DR5 expression significantly attenuated TRAIL-BBR-induced apoptosis, suggesting DR5 to be a mediator of this apoptosis. Our studies indicate that combination of TRAIL and AMPK activator BBR might be an effective means of ameliorating TRAIL-resistance involving DR5 in advanced cancer.

Citing Articles

MLK3 promotes prooncogenic signaling in hepatocellular carcinoma via TGFβ pathway.

Ke R, Viswakarma N, Menhart M, Singh S, Kumar S, Srivastava P Oncogene. 2024; 43(30):2307-2324.

PMID: 38858590 DOI: 10.1038/s41388-024-03055-8.

Effect of Enterococcus faecalis OG1RF on human calvarial osteoblast apoptosis.

Li Y, Sun S, Wen C, Zhong J, Jiang Q BMC Oral Health. 2022; 22(1):279.

PMID: 35804353 PMC: 9264677. DOI: 10.1186/s12903-022-02295-y.

Ets1 mediates sorafenib resistance by regulating mitochondrial ROS pathway in hepatocellular carcinoma.

Vishnoi K, Ke R, Viswakarma N, Srivastava P, Kumar S, Das S Cell Death Dis. 2022; 13(7):581.

PMID: 35789155 PMC: 9253325. DOI: 10.1038/s41419-022-05022-1.

Extraction in cholinium-based magnetic ionic liquid aqueous two-phase system for the determination of berberine hydrochloride in .

Nie L, Song H, Yohannes A, Liang S, Yao S RSC Adv. 2022; 8(44):25201-25209.

PMID: 35542128 PMC: 9082560. DOI: 10.1039/c8ra01745j.

NK Cells Can Preferentially Target Prostate Cancer Stem-like Cells via the TRAIL/DR5 Signaling Pathway.

Seki T, Shimizu Y, Ishii K, Takahama Y, Kato K, Yano T Biomolecules. 2021; 11(11).

PMID: 34827699 PMC: 8615937. DOI: 10.3390/biom11111702.

References

He K, Zheng X, Li M, Zhang L, Yu J . mTOR inhibitors induce apoptosis in colon cancer cells via CHOP-dependent DR5 induction on 4E-BP1 dephosphorylation. Oncogene. 2015; 35(2):148-57. PMC: 4603992. DOI: 10.1038/onc.2015.79. View

Fryer L, Carling D . The Anti-diabetic drugs rosiglitazone and metformin stimulate AMP-activated protein kinase through distinct signaling pathways. J Biol Chem. 2002; 277(28):25226-32. DOI: 10.1074/jbc.M202489200. View

Lu M, Kwan T, Yu C, Chen F, Freedman B, Schafer J . Peroxisome proliferator-activated receptor gamma agonists promote TRAIL-induced apoptosis by reducing survivin levels via cyclin D3 repression and cell cycle arrest. J Biol Chem. 2004; 280(8):6742-51. DOI: 10.1074/jbc.M411519200. View

Plummer R, Attard G, Pacey S, Li L, Razak A, Perrett R . Phase 1 and pharmacokinetic study of lexatumumab in patients with advanced cancers. Clin Cancer Res. 2007; 13(20):6187-94. DOI: 10.1158/1078-0432.CCR-07-0950. View

Grahame Hardie D . AMP-activated/SNF1 protein kinases: conserved guardians of cellular energy. Nat Rev Mol Cell Biol. 2007; 8(10):774-85. DOI: 10.1038/nrm2249. View

Wu G, Burns T, McDonald 3rd E, Jiang W, Meng R, Krantz I . KILLER/DR5 is a DNA damage-inducible p53-regulated death receptor gene. Nat Genet. 1997; 17(2):141-3. DOI: 10.1038/ng1097-141. View

Lee S, Noh H, Sung E, Song I, Kim J, Kwon T . Berberine sensitizes TRAIL-induced apoptosis through proteasome-mediated downregulation of c-FLIP and Mcl-1 proteins. Int J Oncol. 2010; 38(2):485-92. DOI: 10.3892/ijo.2010.878. View

Faubert B, Vincent E, Poffenberger M, Jones R . The AMP-activated protein kinase (AMPK) and cancer: many faces of a metabolic regulator. Cancer Lett. 2014; 356(2 Pt A):165-70. DOI: 10.1016/j.canlet.2014.01.018. View

Zhou J, Huang W, Tao R, Ibaragi S, Lan F, Ido Y . Inactivation of AMPK alters gene expression and promotes growth of prostate cancer cells. Oncogene. 2009; 28(18):1993-2002. PMC: 2679420. DOI: 10.1038/onc.2009.63. View

10.

Krishan S, Richardson D, Sahni S . Adenosine monophosphate-activated kinase and its key role in catabolism: structure, regulation, biological activity, and pharmacological activation. Mol Pharmacol. 2014; 87(3):363-77. DOI: 10.1124/mol.114.095810. View

11.

Viswakarma N, Nair R, Sondarva G, Das S, Ibrahimi L, Chen Z . Transcriptional regulation of mixed lineage kinase 3 by estrogen and its implication in ER-positive breast cancer pathogenesis. Oncotarget. 2017; 8(20):33172-33184. PMC: 5464859. DOI: 10.18632/oncotarget.16566. View

12.

Gwinn D, Shackelford D, Egan D, Mihaylova M, Mery A, Vasquez D . AMPK phosphorylation of raptor mediates a metabolic checkpoint. Mol Cell. 2008; 30(2):214-26. PMC: 2674027. DOI: 10.1016/j.molcel.2008.03.003. View

13.

Pradeep A, Sharma C, Sathyanarayana P, Albanese C, Fleming J, Wang T . Gastrin-mediated activation of cyclin D1 transcription involves beta-catenin and CREB pathways in gastric cancer cells. Oncogene. 2004; 23(20):3689-99. DOI: 10.1038/sj.onc.1207454. View

14.

Sun S, Li Z, Sun L, Yang C, Mei Z, Ouyang W . Results on efficacy and safety of cancer treatment with or without tumor necrosis factor-related apoptosis-inducing ligand-related agents: A meta-analysis. Mol Clin Oncol. 2014; 2(3):440-448. PMC: 3999132. DOI: 10.3892/mco.2014.261. View

15.

Chen K, Tai W, Liu T, Huang H, Lin Y, Shiau C . Sorafenib overcomes TRAIL resistance of hepatocellular carcinoma cells through the inhibition of STAT3. Clin Cancer Res. 2010; 16(21):5189-99. DOI: 10.1158/1078-0432.CCR-09-3389. View

16.

Abdulghani J, Allen J, Dicker D, Liu Y, Goldenberg D, Smith C . Sorafenib sensitizes solid tumors to Apo2L/TRAIL and Apo2L/TRAIL receptor agonist antibodies by the Jak2-Stat3-Mcl1 axis. PLoS One. 2013; 8(9):e75414. PMC: 3784419. DOI: 10.1371/journal.pone.0075414. View

17.

Hurley R, Anderson K, Franzone J, Kemp B, Means A, Witters L . The Ca2+/calmodulin-dependent protein kinase kinases are AMP-activated protein kinase kinases. J Biol Chem. 2005; 280(32):29060-6. DOI: 10.1074/jbc.M503824200. View

18.

Zhang X, Gu L, Li J, Shah N, He J, Yang L . Degradation of MDM2 by the interaction between berberine and DAXX leads to potent apoptosis in MDM2-overexpressing cancer cells. Cancer Res. 2010; 70(23):9895-904. PMC: 2999659. DOI: 10.1158/0008-5472.CAN-10-1546. View

19.

Strekalova E, Malin D, Rajanala H, Cryns V . Metformin sensitizes triple-negative breast cancer to proapoptotic TRAIL receptor agonists by suppressing XIAP expression. Breast Cancer Res Treat. 2017; 163(3):435-447. PMC: 6544153. DOI: 10.1007/s10549-017-4201-0. View

20.

Zhou G, Myers R, Li Y, Chen Y, Shen X, Fenyk-Melody J . Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest. 2001; 108(8):1167-74. PMC: 209533. DOI: 10.1172/JCI13505. View